株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性腎臓病(CKD) - 市場調査、疫学、市場予測

Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 401842
出版日 ページ情報 英文 215 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.30円で換算しております。
慢性腎臓病(CKD) - 市場調査、疫学、市場予測 Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - 2030
出版日: 2020年05月01日 ページ情報: 英文 215 Pages
担当者のコメント
慢性腎臓病(CKD)にフォーカスし、日本、EU5、米国の主要7か国における最新の疫学データ、市場分析、パイプライン動向、主要参入企業動向をまとめたレポートが2020年5月にリリースされました。Delve Insightでは、毎年CDK専門の調査員が当レポートをアップデートしております。
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の慢性腎臓病(CKD)市場について調査し、疾病の概要や現行の治療法、新薬のプロファイル、主要7カ国の市場動向、疫学的予測、市場規模、有病数・罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 イントロダクション

第2章 慢性腎臓病(CKD)市場の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要:慢性腎臓病(CKD)

  • イントロダクション
  • 症状
  • 病因
  • 危険因子
  • 病態生理学
  • 診断
  • 治療

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国における慢性腎臓病(CKD)の総有病数・罹患数
  • 主要7カ国における慢性腎臓病(CKD)の総患者数 - 国別

第5章 慢性腎臓病(CKD)の疫学:国別

  • 米国
    • 仮定と理論的根拠
    • 慢性腎臓病(CKD)の有病数・罹患数
    • 慢性腎臓病(CKD)の症例数:病型別
    • 慢性腎臓病(CKD)の症例数:性別
    • 慢性腎臓病(CKD)の診断数
    • 慢性腎臓病(CKD)の治療可能な症例数
  • EU5カ国
    • 仮定と理論的根拠
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 現行治療

  • 治療アルゴリズム
  • 治療ガイドライン

第7章 アンメットニーズ

第8章 上市済み治療薬

  • 医薬品 A
    • 医薬品の概要
    • 作用機序
    • 規制のマイルストーン
    • 長所と短所
    • 製品プロファイル
  • 医薬品 B

第9章 パイプライン治療薬

第10章 キークロスコンペティション

第11章 新薬

  • 医薬品 C
    • 医薬品概要
    • 臨床試験の詳細
    • 安全性と有効性
    • 長所と短所
    • パイプライン開発動向
    • 製品プロファイル
  • 医薬品 D

第12章 慢性腎臓病(CKD):主要7カ国の市場分析

  • 市場規模
  • 上市済み治療薬の市場シェア
  • 上市済み治療薬の売上高:製品別

第13章 慢性腎臓病(CKD):国別市場分析

  • 米国
    • 市場規模
    • 上市済み治療薬の市場シェア
    • 慢性腎臓病(CKD)の売上高:製品別
    • 新薬とその市場への影響
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第14章 市場成長要因

第15章 市場の障壁

第16章 付録

第17章 調査手法

  • 出典

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Chronic Kidney Disease (CKD) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total Prevalent Patient Population of CKD in 7MM (2017-2030)
  • Table 3: Diagnosed Prevalent Cases of CKD in the United States (2017-2030)
  • Table 4: Prevalent Cases of CKD by stage in the United States (2017-2030)
  • Table 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)
  • Table 6: Comorbidities associated with CKD in the United States (2017-2030)
  • Table 7: Dialysis dependency in the United States (2017-2030)
  • Table 8: Diagnosed Prevalent Cases of CKD in Germany (2017-2030)
  • Table 9: Prevalent Cases of CKD by stage in Germany (2017-2030)
  • Table 10: Prevalent cases of CKD by etiologies in Germany (2017-2030)
  • Table 11: Comorbidities associated with CKD in Germany (2017-2030)
  • Table 12: Dialysis dependency in Germany (2017-2030)
  • Table 13: Diagnosed Prevalent Cases of CKD in France (2017-2030)
  • Table 14: Prevalent Cases of CKD by stage in France (2017-2030)
  • Table 15: Prevalent cases of CKD by etiologies in France (2017-2030)
  • Table 16: Comorbidities associated with CKD in France (2017-2030)
  • Table 17: Dialysis dependency in France (2017-2030)
  • Table 18: Diagnosed Prevalent Cases of CKD in Italy (2017-2030)
  • Table 19: Prevalent Cases of CKD by stage in Italy (2017-2030)
  • Table 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)
  • Table 21: Comorbidities associated with CKD in Italy (2017-2030)
  • Table 22: Dialysis dependency in Italy (2017-2030)
  • Table 23: Diagnosed Prevalent Cases of CKD in Spain (2017-2030)
  • Table 24: Prevalent Cases of CKD by stage in Spain (2017-2030)
  • Table 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)
  • Table 26: Comorbidities associated with CKD in Spain (2017-2030)
  • Table 27: Dialysis dependency in Spain (2017-2030)
  • Table 28: Diagnosed Prevalent Cases of CKD in the United Kingdom (2017-2030)
  • Table 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)
  • Table 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)
  • Table 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)
  • Table 32: Dialysis dependency in the United Kingdom (2017-2030)
  • Table 33: Diagnosed Prevalent Cases of CKD in Japan (2017-2030)
  • Table 34: Prevalent Cases of CKD by stage in Japan (2017-2030)
  • Table 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)
  • Table 36: Comobidities associated with CKD in Japan (2017-2030)
  • Table 37: Dialysis dependency in Japan (2017-2030)
  • Table 38: Summary of ESAs:
  • Table 39: CTAP101, Clinical Trial Description, 2020
  • Table 40: CKD-1101, Clinical Trial Description, 2020
  • Table 41:Daprodustat, Clinical Trial Description, 2020
  • Table 42: Vadadustat, Clinical Trial Description, 2020
  • Table 43:Roxadustat, Clinical Trial Description, 2020
  • Table 44:Empagliflozin, Clinical Trial Description, 2020
  • Table 45:Veverimer, Clinical Trial Description, 2020
  • Table 46: Dapagliflozin, Clinical Trial Description, 2020
  • Table 47:Ziltivekimab, Clinical Trial Description, 2020
  • Table 48:Bardoxolone methyl, Clinical Trial Description 2020
  • Table 49: 7 Major Market Size of CKD in USD Million (2017-2030)
  • Table 50: The US Market size of CKD in USD Million (2017-2030)
  • Table 51: The US market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 52: The US market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 53: Germany Market size of CKD in USD Million (2017-2030)
  • Table 54: Germany market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 55: Germany market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 56: France Market size of CKD in USD Million (2017-2030)
  • Table 57: France market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 58: France market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 59: Italy Market size of CKD in USD Million (2017-2030)
  • Table 60: Italy market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 61: Italy market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 62: Spain Market size of CKD in USD Million (2017-2030)
  • Table 63: Spain market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 64: Spain market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 65: The CKD Market size of CKD in USD Million (2017-2030)
  • Table 66: The UK market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 67: The UK market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 68: Japan Market size of CKD in USD Million (2017-2030)
  • Table 69: Japan market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 70: Japan market size of CKD by Therapies (NDD) in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Total Prevalent Patient Population of CKD in 7MM (2017-2030)
  • Figure 3: Diagnosed prevalent cases of CKD in the United States (2017-2030)
  • Figure 4: Prevalent Cases of CKD by stage in the United States (2017-2030)
  • Figure 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)
  • Figure 6: Comorbidities associated with CKD in the United States (2017-2030)
  • Figure 7: Dialysis dependency in the United States (2017-2030)
  • Figure 8: Diagnosed prevalent cases of CKD in Germany (2017-2030)
  • Figure 9: Prevalent Cases of CKD by stage in Germany (2017-2030)
  • Figure 10: Prevalent cases of CKD by etiologies in the Germany (2017-2030)
  • Figure 11: Comorbidities associated with CKD Germany (2017-2030)
  • Figure 12: Dialysis dependency in Germany (2017-2030)
  • Figure 13: Diagnosed prevalent cases of CKD in the France (2017-2030)
  • Figure 14: Prevalent Cases of CKD by stage in France (2017-2030)

Figure15: Prevalent cases of CKD by etiologies in France (2017-2030)

  • Figure 16: Comorbidities associated with CKD in France (2017-2030)
  • Figure 17: Dialysis dependency in France (2017-2030)
  • Figure 18: Diagnosed prevalent cases of CKD in Italy (2017-2030)
  • Figure 19: Prevalent Cases of CKD by stage in Italy (2017-2030)
  • Figure 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)
  • Figure 21: Comorbidities associated with CKD in Italy (2017-2030)
  • Figure 22: Dialysis dependency in Italy (2017-2030)
  • Figure 23: Diagnosed prevalent cases of CKD in Spain (2017-2030)
  • Figure 24: Prevalent Cases of CKD by stage in Spain (2017-2030)
  • Figure 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)
  • Figure 26: Comorbidities associated with CKD in Spain (2017-2030)
  • Figure 27: Dialysis dependency in Spain (2017-2030)
  • Figure 28: Diagnosed prevalent cases of CKD in the United Kingdom (2017-2030)
  • Figure 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)
  • Figure 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)
  • Figure 31: Comorbidities associated with CKD in the United Kingdom(2017-2030)
  • Figure 32: Dialysis dependency in the United Kingdom (2017-2030)
  • Figure 33: Diagnosed prevalent cases of CKD in Japan (2017-2030)
  • Figure 34: Prevalent Cases of CKD by stage in Japan (2017-2030)
  • Figure 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)
  • Figure 36: Comorbidities associated with CKD in Japan (2017-2030)
  • Figure 37: Dialysis dependency in the Japan (2017-2030)
  • Figure 38: Steps in Manufacturing a Biologic Drug
  • Figure 39: Unmet Needs of Chronic Kidney Disease (CKD)
  • Figure 40: 7 Major Market Size of CKD in USD Million (2017-2030)
  • Figure 41: Market Size of CKD in the United States, USD Millions (2017-2030)
  • Figure 42: The U.S. market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 43: The U.S. market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 44: Market Size of CKD in Germany, USD Millions (2017-2030)
  • Figure 45: Germany market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 46: Germany market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 47: Market Size of CKD in France, USD Millions (2017-2030)
  • Figure 48: France market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 49: France market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 50: Market Size of CKD in Italy, USD Millions (2017-2030)
  • Figure 51: Italy market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 52: Italy market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 53: Market Size of CKD in Spain, USD Millions (2017-2030)
  • Figure 54: Spain market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 55: Spain market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 56: Market Size of CKD in the UK, USD Millions (2017-2030)
  • Figure 57: The UK market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 58: The UK market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 59: Market Size of CKD in Japan, USD Millions (2017-2030)
  • Figure 60: Japan market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 61: Japan market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 62: Key Takeaways for Market Access and Reimbursement of CKD Treatment
  • Figure 63: Market Drivers
  • Figure 64: Market Barriers
目次
Product Code: DIMI0057

DelveInsight's 'Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic kidney disease (CKD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic kidney disease (CKD) - Disease Understanding and Treatment Algorithm

Chronic kidney disease (CKD) is a syndrome where there is persistent alterations in kidney structure, function, or both with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, changes in output or quality of urine and growth delay in children, these changes are most often recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. The most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis.

Several aspects need to be considered when managing patients with CKD, including controlling further nephron injury, normalizing single-nephron hyperfiltration, controlling CKD-related complications and preparing the patient for kidney replacement therapy. Atthe core of these is the principle of 'the earlier, the better', which is the effort to reduce the progression to ESRD and optimize renal outcomes.

The DelveInsight Chronic kidney disease (CKD) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology and risk factors, pathophysiology, disease progression and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Chronic kidney disease.

Chronic kidney disease Epidemiology

The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Chronic kidney disease (CKD) in 7 MM was found to be 122,704,658 in the year 2017.

Chronic kidney disease Drug Chapters

This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details and the latest news and press releases.

The chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as Erythropoietin stimulating agents (ESA), Angiotensin-converting-enzyme inhibitors and Angiotensin receptor blockers (ACE-I and ARBs), Antidiabetics, Secondary Hyperparathyroidism Treatment (SHPT), and Urate Lowering Therapies.

Chronic kidney disease Market Outlook

The Chronic kidney disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Chronic kidney disease in 7MM was found to be USD 7,988.1 million in 2017, and is expected to increase during the course of the study period (2017-2030).Among the 7MM, the United States accounts for the largest market size of CKD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Chronic kidney disease Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic kidney disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic kidney disease Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Chronic kidney disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chronic kidney disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic kidney disease market
  • To understand the future market competition in the Chronic kidney disease market.

Table of Contents

1. Key Insights

2. Executive Summary of Chronic Kidney Disease

3. SWOT Analysis for Chronic Kidney Disease

4. Chronic Kidney Disease (CKD) Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2017
  • 4.2. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. The KDIGO classification of CKD
  • 5.3. Risk factors associated with CKD
  • 5.4. Signs and symptoms
  • 5.5. Pathophysiology

. Complications

  • 5.6. Disease Progression
  • 5.7. Diagnosis, Screening and Prevention

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)

. Country Wise-Epidemiology of CKD

  • 6.3. The United States
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Diagnosed Prevalent cases of CKD
    • 6.3.3. Prevalent cases of CKD by stage
    • 6.3.4. Prevalent cases of CKD by etiologies in the United States
    • 6.3.5. Comorbidities associated with CKD in the United States
    • 6.3.6. Dialysis Dependency in CKD
  • 6.4. EU-5
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Germany
      • 6.4.2.1. Diagnosed Prevalent cases of CKD in Germany
      • 6.4.2.2. Prevalent cases of CKD by stage in Germany
      • 6.4.2.3. Prevalent cases of CKD by etiologies in Germany
      • 6.4.2.4. Comorbidities associated with CKD in Germany
      • 6.4.2.5. Dialysis Dependency in CKD in Germany
    • 6.4.3. France
      • 6.4.3.1. Diagnosed Prevalent cases of CKD in France
      • 6.4.3.2. Prevalent cases of CKD by stage in France
      • 6.4.3.3. Prevalent cases of CKD by etiologies in France
      • 6.4.3.4. Comorbidities associated with CKD in France
      • 6.4.3.5. Dialysis Dependency in CKD in France
    • 6.4.4. Italy
      • 6.4.4.1. Diagnosed Prevalent cases of CKD in Italy
      • 6.4.4.2. Prevalent cases of CKD by stage in Italy
      • 6.4.4.3. Prevalent cases of CKD by etiologies in Italy
      • 6.4.4.4. Comorbidities associated with CKD in Italy
      • 6.4.4.5. Dialysis Dependency in CKD in Italy
    • 6.4.5. Spain
      • 6.4.5.1. Diagnosed Prevalent cases of CKD in Spain
      • 6.4.5.2. Prevalent cases of CKD by stage in Spain
      • 6.4.5.3. Prevalent cases of CKD by etiologies in Spain
      • 6.4.5.4. Comorbidities associated with CKD in Spain
      • 6.4.5.5. Dialysis Dependency in CKD in Spain
    • 6.4.6. The United Kingdom
      • 6.4.6.1. Diagnosed Prevalent cases of CKD in the United Kingdom
      • 6.4.6.2. Prevalent cases of CKD by stage in the United Kingdom
      • 6.4.6.3. Prevalent cases of CKD by etiologies in the United Kingdom
      • 6.4.6.4. Comorbidities associated with CKD in the United Kingdom
      • 6.4.6.5. Dialysis Dependency in CKD in the United Kingdom
  • 6.5. Japan
    • 6.5.1. Assumption and Rationale
    • 6.5.2. Diagnosed Prevalent cases of CKD in Japan
    • 6.5.3. Prevalent cases of CKD by stage in Japan
    • 6.5.4. Prevalent cases of CKD by etiologies in Japan
    • 6.5.5. Comorbidities associated with CKD in Japan
    • 6.5.6. Dialysis Dependency in CKD in Japan

7. Treatment and Management

  • 7.1. Biosimilars
  • 7.2. Treatment guidelines for CKD
    • 7.2.1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline
    • 7.2.2. NICE Guidelines
  • 7.3. Case Study
    • 7.3.1. Improving Outcomes for Patients with Chronic Kidney Disease
  • 7.4. Patient Journey for CKD

8. Unmet Needs

9. Marketed Products

  • 9.1. Epogen (Epoetin alfa): Amgen
    • 9.1.1. Product Description
    • 9.1.2. Product Developmental Activity
    • 9.1.3. Safety and Efficacy
  • 9.2. Aranesp (Darbepoetin alfa): Amgen
    • 9.2.1. Product Description
    • 9.2.2. Product Developmental Activity
    • 9.2.3. Safety and Efficacy
  • 9.3. Feraheme: Amag Pharmaceuticals
    • 9.3.1. Product Description
    • 9.3.2. Product Developmental Activity
    • 9.3.3. Safety and Efficacy
  • 9.4. Parsabiv (etelcalcetide): Amgen
    • 9.4.1. Product Description
    • 9.4.2. Product Developmental Activity
    • 9.4.3. Safety and Efficacy
  • 9.5. Sensipar (Cinacalcet): Amgen
    • 9.5.1. Product Description
    • 9.5.2. Product Developmental Activity
    • 9.5.3. Safety and Efficacy
  • 9.6. Auryxia: Keryx Biopharmaceuticals
    • 9.6.1. Product Description
    • 9.6.2. Product Developmental Activity
    • 9.6.3. Safety and Efficacy
  • 9.7. Paricalcitol (Zemplar): AbbVie
    • 9.7.1. Product Description
    • 9.7.2. Product Developmental Activity
    • 9.7.3. Safety and Efficacy
  • 9.8. Velphoro(Sucroferric oxyhydroxide): Vifor Pharma
    • 9.8.1. Product Description
    • 9.8.2. Product Developmental Activity
    • 9.8.3. Safety and Efficacy
  • 9.9. Rayaldee (CTAP101): OPKO IP Holdings II, Inc.|OPKO Health, Inc.
    • 9.9.1. Drug Description
    • 9.9.2. Other Developmental Activities
    • 9.9.3. Clinical Development
      • 9.9.3.1. Clinical Trials Information
    • 9.9.4. Safety and Efficacy
  • 9.1. CKD-11101: Chong Kun Dang Pharmaceuticals
    • 9.10.1. Product Description
    • 9.10.2. Other Developmental Activities
    • 9.10.3. Clinical Development
      • 9.10.3.1. Clinical trials information
    • 9.10.4. Safety and Efficacy

10. Emerging Therapies

  • 10.1. Daprodustat: GlaxoSmithKline
    • 10.1.1. Drug Description
    • 10.1.2. Other Developmental Activities
    • 10.1.3. Clinical Development
      • 10.1.3.1. Clinical trials information
    • 10.1.4. Safety and Efficacy
  • 10.2. Vadadustat: Akebia Therapeutics
    • 10.2.1. Drug Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
      • 10.2.3.1. Clinical trials information
    • 10.2.4. Safety and Efficacy
  • 10.3. Roxadustat: FibroGen/Astellas Pharma/ AstraZeneca
    • 10.3.1. Drug Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
      • 10.3.3.1. Clinical trials information
    • 10.3.4. Safety and Efficacy
  • 10.4. Empagliflozin: Boehringer Ingelheim
    • 10.4.1. Drug Description
    • 10.4.2. Other Developmental Activities
    • 10.4.3. Clinical Development
      • 10.4.3.1. Clinical trials information
    • 10.4.4. Safety and Efficacy
  • 10.5. Veverimer: Tricida
    • 10.5.1. Drug Description
    • 10.5.2. Other Developmental Activities
    • 10.5.3. Clinical Development
      • 10.5.3.1. Clinical trials information
    • 10.5.4. Safety and Efficacy
  • 10.6. Dapagliflozin: AstraZeneca
    • 10.6.1. Drug Description
    • 10.6.2. Other Developmental Activities
    • 10.6.3. Clinical Development
      • 10.6.3.1. Clinical trials information
    • 10.6.4. Safety and Efficacy
  • 10.7. Ziltivekimab: Corvidia Therapeutics
    • 10.7.1. Product Description
    • 10.7.2. Clinical Development
      • 10.7.2.1. Clinical Trials Information
    • 10.7.3. Safety and Efficacy
  • 10.8. Bardoxolone methyl: Reata Pharmaceuticals.
    • 10.8.1. Drug Description
    • 10.8.2. Other Developmental Activities
    • 10.8.3. Clinical Development
    • 10.8.4. Safety and Efficacy

11. CKD: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Total Market Size of CKD in 7MM

12. Market Outlook: 7 MM

13. Country-wise Market Size

14. United States

  • 14.1. Total Market size of CKD
  • 14.2. CKD Market Size by Therapies (Dialysis Dependent)
  • 14.3. CKD Market Size by Therapies (Non-Dialysis Dependent)

15. EU5 Countries

  • 15.1. Germany
    • 15.1.1. Total Market size of CKD
    • 15.1.2. CKD Market Size by Therapies (DD)
    • 15.1.3. CKD Market Size by Therapies (NDD)
  • 15.2. France
    • 15.2.1. Total Market size of CKD
    • 15.2.2. CKD Market Size by Therapies (DD)
    • 15.2.3. CKD Market Size by Therapies
  • 15.3. Italy
    • 15.3.1. Total Market size of CKD
    • 15.3.2. CKD Market Size by Therapies (DD)
    • 15.3.3. CKD Market Size by Therapies
  • 15.4. Spain
    • 15.4.1. Total Market size of CKD
    • 15.4.2. CKD Market Size by Therapies (DD)
    • 15.4.3. CKD Market Size by Therapies (NDD)
  • 15.5. United Kingdom
    • 15.5.1. Total Market size of CKD
    • 15.5.2. CKD Market Size by Therapies (DD)
    • 15.5.3. CKD Market Size by Therapies (NDD)

16. Japan

  • 16.1. Total Market size of CKD
  • 16.2. CKD Market Size by Therapies (DD)
  • 16.3. CKD Market Size by Therapies (NDD)

17. Market Access and Reimbursement

19. Market Drivers

20. Market Barriers

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight